Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
The Clinical Course of Advanced Dementia
NEJM 361:1529-1538, 1595, Mitchell,S.,et al, 2009
Mild Cognitive Impairment
Lancet 367:1262-1270, Gauthier,S.,et al, 2006
A 32-Year Prospective Study of Change in Body Weight and Incident Dementia
Arch Neurol 62:55-60,20, Stewart,R.,et al, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Functional Deficits in Patients with Mild Cognitive Impairment
Neurol 58:758-764, Tabert,M.H.,et al, 2002
A Reevaluation of the Duration of Survival After the Onset of Dementia
NEJM 344:1111-1116, Wolfson,C.,et al, 2001
Positron Emission Tomography in Evaluation of Dementia
JAMA 286:2120-2127,2194, Silverman,D.H.S.,et al, 2001
Progression of Alzheimer's Disease in Black and White Patients
Neurol 51:154-158, Fillenbaum,G.G.,et al, 1998
Progression to Dementia in Patients with Isolated Memory Loss
Lancet 349:763-765, Bowen,J.,et al, 1997
AIDS in the Elderly:New York City Vital Statistics
J Emerg Med 14:19-23, Gaeta,T.J.,et al, 1996
Medical Aspects of the Persistent Vegetative State
NEJM 330:1499-1508, 1572-15791994., Annas,G.J.,et al, 1994
A Population-Based Study of Dementia in 85-Year-Olds
NEJM 328:153-158, 203-2051993., Skoog,I.,et al, 1993
A Controlled Study of Survival with Dementia
Arch Neurol 44:1122-1126, Martin,D.C.,et al, 1987
Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons with Dementia
Neurol 105: e213717, Zissimopoulos, J.,et al, 2025
Tau Positron Emission Tomography for Predicting Dementia in Individuals with Mild Cognitive Impairment
JAMA Neurol 81:845-856, Groot,C.,et al, 2024
The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Outcomes after Diagnosis of Mild Cognitive Impairment in a Large Autopsy Series
Ann Neurol 81:549-559, Abner, E.L.,et al, 2017
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Neurodegenerative causes of death among retired National Football League Players
Neurol 79:1970-1974, Lehman, E.,et al, 2012
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Survival Times in People with Dementia: Analysis From Population Based Cohort Study With 14 Year Follow-Up
BMJ 336:258-262,225, Xie,J.,et al, 2008
Estimating Prognosis for Nursing Home Residents with Advanced Dementia
JAMA 291:2734-2740, Mitchell,S.L.,et al, 2004
Identification of New Presenilin Gene Mutations in Early-Onset Familial Alzheimer Disease
Arch Neurol 60:1541-1544,1521, Tedde,A.,et al, 2003
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Natural History of Mild Cognitive Impairment in Older Persons
Neurol 59:198-205, Bennett,D.A.,et al, 2002
Incidence and Outcome of Mild Cognitive Impairment in a Population-Based Prospective Cohort
Neurol 59;1594-1599, Larrieu,S.,et al, 2002
Survival in End-Stage Dementia Following Acute Illness
JAMA 284: 47-52, 87, Morrison,R.S. & Siu,A.L., 2000
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
The APOE-e4 Allele and the Risk of Alzheimer Disease Among AFrican Americans, Whites and Hispanics
JAMA 279:751-755, 7881998., Tang,M.,et al, 1998
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Increased Risk of Mortality in Alzheimer's Disease Patients with Higher Education
Neurol 49:798-802, Geerlings,M.I.,et al, 1997
Genetic Testing for Alzheimer Disease, Practical and Ethical Issues
Arch Neurol 54:1226-1229, Roses,A.D., 1997
Complete Genomic Screen in Late-Onset Familial Alzheimer Disease, Evidence for a New Locus on Chromosome 12
JAMA 278:1237-1241, 12821997., Pericak-Vance,M.A.,et al, 1997
Lewy Body Disease and Dementia
Arch Int Med 156:487-493, Kalra,S.,et al, 1996
Apolipoprotein E and Cognitive Decline in Alzheimer's Disease
Neurol 47:317-320, Plassman,B.L.&Breitner,J.C.S., 1996
Long-Term Tacrine (Cognex) Treatment:Effects on Nursing Home Placement and Mortality
Neurol 47:166-177, Knopman,D.,et al, 1996
Genetic Factors in Alzheimer's Disease:A Review of Recent Advances
Ann Neurol 40:829-840, Levy-Lahad,E.&Bird,T.D., 1996
Increased Risk of Mortality in Alzheimer's Disease Patients with More Advanced Educataional and Occupational Attainment
Ann Neurol 37:590-595, Stern,Y.,et al, 1995
Apolipoprotein E Genotype in Patients with Alzheimer's Disease:Implications for Risk of Dementia Among Relatives
Ann Neurol 38:797-808, Farrer,L.A.,et al, 1995
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Increased Risk of Alzheimer's Disease in Mothers of Adults with Down's Syndrome
Lancet 344:353-356, Schupf,N.,et al, 1994